Evaluation of the efficacy of sofosbuvir and ribavirin for Japanese hepatitis C patients: a prospective study in real-life settings.

Evaluation of the efficacy of sofosbuvir and ribavirin for Japanese hepatitis C patients: a prospective study in real-life settings. - the efficacy of sofosbuvir and ribavirin for Japanese hepatitis C patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019469

Enrollment

100

Registered

2015-11-01

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

sofosbuvir and ribavirin sofosbuvir 400mg once daily, and ribavirin twice daily (600 mg daily in patients with a body weight of 60 kg and under, 800 mg daily in patients weighing from 60 kg to 80 kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C and compensated cirrhotic patients with HCV genotype 2 naive and DAA treatment experienced patients

Exclusion criteria

Exclusion criteria: decompensated cirrhosis severe anemia

Design outcomes

Primary

Measure	Time frame
sustained virological response (SVR) at 12 weeks and 24 weeks after the end of treatment	—

Secondary

Measure	Time frame
incidence rate of adverse events	—

Countries

Japan

Contacts

Public ContactHitomi Sezaki

Toranomon Hospital hepatology

hitomis@mx1.harmonix.ne.jp03-3588-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026